ABVC BioPharma Receives $100,000 Milestone Payment in Vitargus® Licensing Deal with ForSeeCon

ABVC BioPharma, Inc. has received an additional $100,000 licensing payment from ForSeeCon Eye Corporation under the global licensing agreement covering the company's innovative vitreous substitute, Vitargus®. With this latest payment, ABVC has now collected a cumulative $495,000 in cash licensing payments from ForSeeCon.

The overall licensing structure includes $30 million already delivered in equity consideration, represented by 5 million ForSeeCon shares based on an internal equity valuation, $3.5 million in total cash licensing payments, and up to $60 million in sales royalties payable if Vitargus® reaches commercialization. This blended structure of equity, milestone cash, and royalties underscores both the near-term liquidity and long-term upside potential embedded in the ForSeeCon collaboration.

Vitargus® is believed to be the world's first biodegradable vitreous substitute designed to replace the gel-like substance in the eye during retinal detachment surgery. Unlike current silicone oil or gas bubble solutions, Vitargus® is naturally absorbed and allows patients to maintain upright vision during recovery, eliminating the need for prolonged face-down positioning.

The market potential for Vitargus® is substantial, with the global vitreous substitute market valued at approximately $2.5 billion in 2024 and projected to reach $4.1 billion by 2033, expanding at a CAGR of 6.3% according to Verified Market Reports. The broader retinal surgery devices market was estimated at $2.82 billion in 2024 and is expected to grow to $4.76 billion by 2030, at a CAGR of 9.2% according to Grand View Research.

Dr. Uttam Patil, ABVC's Chief Executive Officer, stated that this milestone payment highlights the continued progress of the Vitargus® licensing collaboration. With $495,000 already received in cash, over $3 million still available to receive and equity holdings in ForSeeCon, ABVC is strategically positioned to capture both near-term financial benefits and long-term commercial upside. Jerry Chang, CEO of ForSeeCon Eye Corporation, added that Vitargus continues to generate interest globally and their milestone payment reflects confidence in the product's regulatory and commercial trajectory.

This agreement with ForSeeCon further strengthens ABVC's financial and strategic foundation in ophthalmology. By combining upfront equity, milestone cash payments and substantial royalty opportunities, ABVC has secured a licensing deal with a total potential value of $63.5 million. With both immediate cash flows and long-term revenue streams, ABVC is positioning itself to deliver transformational shareholder value while advancing Vitargus® to address the multi-billion-dollar global market for retinal disease treatments as reported by Grand View Research.